Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

US-based radiopharmaceutical company Lantheus has announced a definitive agreement to acquire clinical-stage radiopharma contract development and manufacturing organisation (CDMO) Evergreen ...

Lantheus Holdings Inc (($LNTH)) has held its Q4 earnings call. Read on for the main highlights of the call. Lantheus Holdings Inc. recently held ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) began 2025 with a pair of potentially ...

Evergreen Theragnostics has the potential to ... to establish a payment based on average sales price or ASP. Lantheus has been reporting Pylarify’s ASP since launch, and we believe other ...

Lantheus is enhancing its radiopharmaceutical ... the agreements to acquire Life Molecular and Evergreen Theragnostics. Both acquisitions are expected to close in the second half of 2025, subject ...